Pharma major Lupin Limited announced its financial results for the second quarter ended September 30, 2026. The company reported a 14.0% year-over-year increase in sales, reaching INR 77,855 Mn. However, Profit After Tax (PAT) saw a decline of 22.2%, standing at INR 11,553 Mn compared to INR 14,848 Mn in the prior year’s quarter. EBITDA also decreased by 10.7%.
Lupin Reports Q2 FY2027 Financial Highlights
Pharma major Lupin Limited has announced its financial performance for the second quarter of the fiscal year 2027, ending September 30, 2026. The company registered a consolidated revenue from operations of INR 78,273 Mn, marking an increase of 11.1% compared to INR 70,475 Mn in Q2 FY2026. Total Product Sales for the quarter grew by 14.0% year-on-year to INR 77,855 Mn.
Key Financial Metrics
Gross Profit (excluding other operating income) for the quarter stood at INR 57,774 Mn, up 15.4% from INR 50,066 Mn in Q2 FY2026, with a gross margin of 74.2%. However, Profit Before Tax (PBT) declined by 21.3% to INR 15,796 Mn from INR 20,070 Mn in the same period last year. Profit After Tax (PAT) also saw a decrease of 22.2%, amounting to INR 11,553 Mn compared to INR 14,848 Mn in Q2 FY2026.
Sales Performance by Region
The company’s sales mix for Q2 FY2027 shows the U.S. market contributing 39% with sales of INR 30,202 Mn, up 9.3% year-on-year. India accounted for 31% of sales, with INR 23,836 Mn, an increase of 14.7%. Other Developed Markets contributed 15% (INR 11,823 Mn, up 45.7%), while Emerging Markets represented 11% (INR 8,908 Mn, down 3.5%). Global API sales increased by 20.2% to INR 3,086 Mn.
Operational and R&D Highlights
Operational highlights include 4 ANDA and 1 NDA 505(b)(2) approvals from the U.S. FDA, with 1 product launched in the quarter. Lupin continues to be a significant player in the U.S. generic market. Investment in R&D for the quarter was INR 6,181 Mn (7.9% of sales), an increase from INR 5,222 Mn (7.6% of sales) in Q2 FY2026.
Managing Director, Mr. Nilesh Gupta, expressed confidence in the company’s long-term growth prospects, supported by its portfolio and sustained profitability, while acknowledging near-term challenges.
Source: BSE
